Tag

Boston Scientific

All articles tagged with #boston scientific

business29 days ago•30 min saved

Boston Scientific posts stronger-than-expected 2025 results, lifts 2026 outlook

Boston Scientific reported Q4 2025 net sales of $5.286 billion, up 15.9% year over year, with GAAP net income of $672 million ($0.45 per share) and adjusted EPS of $0.80. For all of 2025, net sales totaled $20.074 billion (up 19.9%), GAAP net income was $2.898 billion ($1.94 per share), and adjusted EPS was $3.06. For 2026, the company guides net sales growth of about 10.5–11.5% on a reported basis (10.0–11.0% organic) and adjusted EPS of $3.43–$3.49, plus Q1 2026 guidance of 10.5–12.0% net sales growth (8.5–10.0% organic) and EPS $0.78–$0.80. The release also notes ongoing product approvals, trials, and strategic acquisitions (e.g., Penumbra, Valencia Technologies) and the discontinuation of ACURATE neo2/Prime valve sales.

via www.bostonscientific.com|

#2026-guidance #boston-scientific #business

business1 month ago•5 min saved

Boston Scientific to Acquire Penumbra for $14.5 Billion, Expanding Stroke Tech

Boston Scientific signed a cash-and-stock deal to acquire Penumbra for about $14.5 billion, valuing Penumbra at $374 per share and aiming to close later this year pending approvals. Penumbra’s portfolio spans neurovascular and vascular devices, including thrombectomy systems, potentially broadening Boston Scientific’s growth in high-potential markets. Financing consists of roughly 73% cash and 27% stock, with an expected near-term EPS dilution followed by accretion as synergies materialize.

via MassDevice|

#boston-scientific #business #medical-devices

business1 month ago•11 min saved

Boston Scientific set to buy Penumbra for $14.5B, expanding vascular devices portfolio

Boston Scientific plans to acquire Penumbra for about $14.5 billion in cash and stock, gaining Penumbra’s thrombectomy and embolization devices to broaden its vascular portfolio. The deal values Penumbra at $374 per share and is expected to close in 2026 pending shareholder and regulatory approvals, with Penumbra generating about $1.4 billion in revenue for 2025. Analysts say the price is fair and the acquisition aligns with a trend of medtech consolidation.

via MedTech Dive|

#boston-scientific #business #manda

business1 month ago•13 min saved

Boston Scientific to acquire Penumbra in $14.5B push into thrombectomy and neurovascular care

Boston Scientific announced a definitive agreement to acquire Penumbra in a cash-and-stock deal valued at about $14.5 billion (Penumbra at $374/share), creating a scaled entry into mechanical thrombectomy and neurovascular therapies. The transaction finances roughly 73% cash and 27% Boston Scientific stock (about $11 billion cash financed with cash on hand and new debt) and is expected to close in 2026 pending stockholder and regulatory approvals. Penumbra reported about $1.4 billion in revenue for 2025. Penumbra stockholders may elect cash or Boston Scientific shares; Adam Elsesser plans to take Boston Scientific stock for all his Penumbra shares. The deal is dilutive to GAAP earnings in the near term and to adjusted EPS in the near term, with accretion expected in later years.

via PR Newswire|

#acquisition #boston-scientific #business

business-and-finance2 years ago•3 min saved

Boston Scientific's $3.7 Billion Acquisition of Axonics

Boston Scientific has agreed to acquire Axonics for approximately $3.7 billion, aiming to strengthen its urology business and expand into the high-growth sacral neuromodulation market. Axonics, based in California, develops neuromodulation systems for urinary and bowel dysfunction treatment. The acquisition is expected to be completed in the first half of 2024, with Boston Scientific projecting a highly accretive impact on its urology business in 2024. This move aligns with Boston Scientific's strategy of pursuing M&A to reinforce category leadership and enter faster growth markets.

via Mass Device|

#acquisition #axonics #boston-scientific

business2 years ago•0 min saved

Boston Scientific's $3.7 Billion Acquisition of Axonics

Boston Scientific has announced its acquisition of Axonics for approximately $3.7 billion in cash, with the deal aimed at expanding its portfolio to better serve urologists. The agreement values Axonics at $71 per share, giving the company an equity value of $3.7 billion and an enterprise value of $3.4 billion.

via The Wall Street Journal|

#acquisition #axonics #boston-scientific

business2 years ago•6 min saved

"Boston Scientific to Acquire Axonics, Inc. in New Agreement"

Boston Scientific has agreed to acquire Axonics, Inc. for approximately $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' product portfolio includes sacral neuromodulation (SNM) therapy systems for overactive bladder and fecal incontinence, with the recent FDA approval of its fourth-generation neurostimulator. The acquisition is expected to strengthen Boston Scientific's ability to serve urologists and provide opportunities to expand access to care for patients. The transaction is anticipated to be completed in the first half of 2024 and is expected to have a highly accretive impact on Boston Scientific's urology business in 2024.

via PR Newswire|

#acquisition #axonics #boston-scientific

healthcare2 years ago•5 min saved

Boston Scientific Acquires Relievant Medsystems for $850M in Back Pain Ablation Tech Deal

Boston Scientific has announced its agreement to acquire Relievant Medsystems, a medical technology company specializing in treating chronic low back pain. The acquisition will expand Boston Scientific's neuromodulation portfolio and provide more treatment options for individuals with vertebrogenic pain. The transaction includes an upfront cash payment of $850 million, with additional contingent payments based on sales performance. The Intracept Intraosseous Nerve Ablation System developed by Relievant is the only FDA-cleared system for vertebrogenic pain and offers a minimally invasive outpatient procedure. The deal is expected to close in the first half of 2024.

via PR Newswire|

#acquisition #boston-scientific #chronic-low-back-pain

healthcare2 years ago•2 min saved

Boston Scientific's Breakthrough in Atrial Fibrillation Treatment Propels Stock Surge

Boston Scientific is expected to receive FDA approval for its pulsed field ablation method of treating abnormal heartbeats, which uses electrical pulses to selectively kill problematic cardiac cells. In a comparison with thermal ablation, the newer approach showed similar efficacy and safety profiles. The company's stock surged 6% on the news. Analysts believe that this development positions Boston Scientific to capture a significant share of the nearly $8 billion electrophysiology market.

via Investor's Business Daily|

#abnormal-heartbeats #boston-scientific #electrophysiology-market

business2 years ago•2 min saved

"Stocks Soaring: 3M, XPeng, Boston Scientific, and More Make Big Moves"

RPT Realty shares surged 17% after Kimco Realty announced its acquisition of the real estate investment trust in a $2 billion all-stock deal. Mister Car Wash stock advanced 6.1% following an upgrade by Piper Sandler. Boston Scientific jumped nearly 6% after announcing positive results for its treatment for abnormal heartbeats. CrowdStrike fell 3.7% after a downgrade by Morgan Stanley. 3M saw a 5.2% increase in its stock price after reaching a tentative deal to settle lawsuits over its combat ear plugs. Xpeng, the Chinese electric car company, rose 5.3% after acquiring Didi's smart electric car development business.

via CNBC|

#3m #boston-scientific #business

business2 years ago•1 min saved

Boston Scientific Takeover Talks Cause SWAV Stock to Plummet.

The potential deal between Boston Scientific and Shockwave Medical reportedly fell apart due to disagreement on price, causing Shockwave's stock to drop by 6.3%. The deal could have bolstered Boston Scientific's cardiovascular portfolio with Shockwave's intravascular lithotripsy technology. Shockwave is expected to report a 103% increase in earnings and a 57% increase in sales for Q1. Analysts predict Shockwave's earnings to increase by 35% and sales to surge by 37% for the year.

via Investor's Business Daily|

#boston-scientific #business #cardiovascular-portfolio